$6.91
1.02% yesterday
Nasdaq, Dec 24, 08:47 pm CET
ISIN
US9216591084
Symbol
VNDA

Vanda Pharmaceuticals Inc. Stock price

$6.91
+2.02 41.31% 1M
+2.41 53.56% 6M
+2.12 44.26% YTD
+2.08 43.06% 1Y
+0.04 0.58% 3Y
-6.37 47.97% 5Y
-2.69 28.02% 10Y
-2.77 28.62% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.07 1.02%
ISIN
US9216591084
Symbol
VNDA
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$293.8m
Shares outstanding
59.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
82.1%
Return on Equity
-3.5%
ROCE
-25.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$212.1m | $222.6m
EBITDA
$-114.1m | $-38.0m
EBIT
$-121.1m | $-144.6m
Net Income
$-84.2m | $-139.1m
Free Cash Flow
$-83.0m
Growth (TTM | estimate)
Revenue
11.1% | 12.0%
EBITDA
-268.0% | -13.9%
EBIT
-223.1% | -255.7%
Net Income
-413.7% | -636.0%
Free Cash Flow
-355.8%
Margin (TTM | estimate)
Gross
94.4%
EBITDA
-53.8% | -17.1%
EBIT
-57.1%
Net
-39.7% | -62.5%
Free Cash Flow
-39.1%
More
EPS
$-1.4
FCF per Share
$-1.4
Short interest
8.2%
Employees
368
Rev per Employee
$540.0k
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
80%
Hold
20%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
212 212
11% 11%
100%
- Direct Costs 12 12
3% 3%
6%
200 200
12% 12%
94%
- Selling and Administrative Expenses 214 214
64% 64%
101%
- Research and Development Expense 100 100
27% 27%
47%
-114 -114
268% 268%
-54%
- Depreciation and Amortization 7.01 7.01
8% 8%
3%
EBIT (Operating Income) EBIT -121 -121
223% 223%
-57%
Net Profit -84 -84
414% 414%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
10 days ago
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the e...
Neutral
PRNewsWire
14 days ago
WASHINGTON , Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026.
Neutral
PRNewsWire
21 days ago
WASHINGTON , Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant. The lift followed Vanda's formal dispute resolution request and an expedited re-review conducted by CD...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today